CoChat

Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis

Open access

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.

Abstract

Background: Uncertainty remains regarding the effectiveness of treatments for patients diagnosed with both an alcohol use disorder (AUD) and depressive disorder. This study aimed to compare the effectiveness of clinical interventions for improving symptoms of adults with co-occurring AUDs and depressive disorders. Methods and findings: We searched CINAHL, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Excerpta Medica Database, International Clinical Trials Registry Platform (ICTRP), PubMed, PsycINFO, and Web of Science from inception to December 2020. We included randomized controlled trials (RCTs) evaluating clinical interventions for adults with co-occurring AUDs and depressive disorders. Two independent reviewers extracted study-level information and outcome data. We assessed risk of bias using the Cochrane Risk of Bias tool, used frequentist random effects models for network meta-analyses, and rated our confidence in effect estimates using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Primary outcomes were remission from depression and alcohol use. Secondary outcomes were depressive symptoms, alcohol use, heavy drinking, health-related quality of life, functional status, and adverse events. We used standardized mean differences (SMDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes to estimate intervention effects. Overall, 36 RCTs with 2,729 participants evaluated 14 pharmacological and 4 psychological interventions adjunctive to treatment as usual (TAU). Studies were published from 1971 to 2019, conducted in 13 countries, and had a median sample size of 50 participants (range: 14 to 350 participants). We have very low confidence in all estimates of intervention effects on our primary outcomes (i.e., remission from depression and remission from alcohol use). We have moderate confidence that cognitive behavioral therapies (CBTs) demonstrated greater benefit than no additional treatment (SMD = −0.84; 95% confidence interval [CI], −1.05 to −0.63; p < 0.001) for depressive symptoms and low confidence (SMD = −0.25; 95% CI, −0.47 to −0.04; p = 0.021) for alcohol use. We have low confidence that tricyclic antidepressants (TCAs) demonstrated greater benefit than placebo (SMD = −0.37; 95% CI, −0.72 to −0.02, p = 0.038) for depressive symptoms. Compared with placebo, we have moderate confidence that selective serotonin reuptake inhibitors (SSRIs) demonstrated greater benefit for functional status (SMD = −0.92; 95% CI, −1.36 to −0.47, p < 0.001) and low confidence for alcohol use (SMD = −0.30; 95% CI, −0.59 to −0.02, p = 0.039). However, we have moderate confidence that patients receiving SSRIs also were more likely to experience an adverse event (OR = 2.20; 95% CI, 0.94 to 5.16, p = 0.07). We have very low confidence in all other effect estimates, and we did not have high confidence in any effect estimates. Limitations include the sparsity of evidence on intervention effects over the long term, risks of attrition bias, and heterogeneous definitions of adverse events in the evidence base. Conclusions: We are very uncertain about the existence (or not) of any non-null effects for our primary outcomes of remission from depression and remission from alcohol use. The available evidence does suggest that CBTs likely reduced, and TCAs may have resulted in a slight reduction of depressive symptoms. SSRIs likely increased functional status, and SSRIs and CBTs may have resulted in a slight reduction of alcohol use. However, patients receiving SSRIs also likely had an increased risk of experiencing an adverse event. In addition, these conclusions only apply to postintervention and are not against active comparators, limiting the understanding of the efficacy of interventions in the long term as well as the comparative effectiveness of active treatments. As we did not have high confidence in any outcomes, additional studies are warranted to provide more conclusive evidence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1003822

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Study flow diagram. Note: A single study can have multiple publications and therefore citations. Therefore, in the “included” box in the flow diagram, we have noted how many studies are reported by included citations. RCT, randomized controlled trial.
Fig 1 Study flow diagram. Note: A single study can have multiple publications and therefore citations. Therefore, in the “included” box in the flow diagram, we have noted how many studies are reported by included citations. RCT, randomized controlled trial.CC BY · PubMed Central
Fig 2 Network structure. (a) Pharmacological network structure by intervention class. (b) Psychological network structure by intervention class. Notes: The size of the width of each edge (line) is based on the number of direct comparisons between the 2 connected interventions. The shaded area indicates a “closed” loop (i.e., there is at least 1 study that compares one alternative intervention to an intervention with another alternative to that intervention), allowing the comparison of effect estimates from direct evidence with effect estimates from indirect evidence. AAP, atypical antipsychotic; MRI, monoamine reuptake inhibitor; nAChR, nonselective noncompetitive antagonists of the nicotinic acetylcholine receptor; NRI, norepinephrine reuptake inhibitor; SARI, serotonin antagonist and reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TeCA, tetracyclic antidepressant.
Fig 2 Network structure. (a) Pharmacological network structure by intervention class. (b) Psychological network structure by intervention class. Notes: The size of the width of each edge (line) is based on the number of direct comparisons between the 2 connected interventions. The shaded area indicates a “closed” loop (i.e., there is at least 1 study that compares one alternative intervention to an intervention with another alternative to that intervention), allowing the comparison of effect estimates from direct evidence with effect estimates from indirect evidence. AAP, atypical antipsychotic; MRI, monoamine reuptake inhibitor; nAChR, nonselective noncompetitive antagonists of the nicotinic acetylcholine receptor; NRI, norepinephrine reuptake inhibitor; SARI, serotonin antagonist and reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TeCA, tetracyclic antidepressant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 102 references

Research works printed but not linked: 1

  1. JPT Higgins, 2016, Methodological Expectations of Cochrane Intervention Reviews

Cited by

See all 31

Metadata

Authors
Grant, S., Azhar, G., Han, E., Booth, M., Motala, A., Larkin, J., & Hempel, S.
Affiliations
RAND Corporation (US)
Corresponding author
Grant, Sean
Venue
PLOS Medicine
Published
2021-10-08
Volume
18
Issue
10
Pages
e1003822
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W3117035996
Cited by
31
References
102
Citations by year
2026: 8 · 2025: 8 · 2024: 7 · 2023: 4 · 2022: 3 · 2021: 1
FWCI
0.57
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
U.S. Department of Defense (Psychological Health Center of Excellence)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
alcoholism, depressive disorders, comorbidities, dual diagnosis, cognitive behavioral therapy, tricyclic antidepressants, selective serotonin reuptake inhibitors, antidepressant augmentation, adjunctive pharmacotherapy, psychological intervention, depression remission, health-related quality of life, functional status, adverse events, treatment effectiveness comparison, adults, treatment-resistant depression, heavy drinking
MeSH terms
Adult, Alcoholism, Depression, Female, Humans, Male, Middle Aged, Quality of Life, Remission Induction, Risk, Substance Withdrawal Syndrome, Comorbidity, Publication Bias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1371/journal.pmed.1003822
The paper
Grant, S., Azhar, G., Han, E., Booth, M., Motala, A., Larkin, J., & Hempel, S. (2021). Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1003822

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.